Stockscreener 앱 받기
89.59
1.29%
1.14
시장 영업 전:
89.68
0.09
+0.10%
전일 마감가:
$88.45
열려 있는:
$88.96
하루 거래량:
860.97K
Relative Volume:
0.72
시가총액:
$22.66B
수익:
$3.26B
순이익/손실:
$-1.45B
주가수익비율:
-15.26
EPS:
-5.871
순현금흐름:
$1.18B
1주 성능:
-4.12%
1개월 성능:
-9.82%
6개월 성능:
-6.67%
1년 성능:
-19.39%
1일 변동 폭
$88.91
$91.08
1주일 범위
$87.95
$97.44
52주 변동 폭
$79.52
$124.00
바이오앤테크 Stock (BNTX) Company Profile
Compare BNTX vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BNTX
Biontech Se Adr
|
89.59 | 22.37B | 3.26B | -1.45B | 1.18B | -5.871 |
VRTX
Vertex Pharmaceuticals Inc
|
441.74 | 108.72B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
628.73 | 64.89B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
842.27 | 50.57B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
303.64 | 39.06B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
155.69 | 33.16B | 742.00K | -1.37B | -1.07B | -7.0731 |
바이오앤테크 Stock (BNTX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-02-02 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2026-01-16 | 업그레이드 | Goldman | Neutral → Buy |
| 2025-06-05 | 재확인 | H.C. Wainwright | Buy |
| 2025-05-29 | 개시 | Goldman | Neutral |
| 2025-03-13 | 개시 | Citigroup | Buy |
| 2025-01-10 | 개시 | Truist | Buy |
| 2024-12-11 | 개시 | Wells Fargo | Overweight |
| 2024-12-02 | 재확인 | BMO Capital Markets | Outperform |
| 2024-11-19 | 개시 | Berenberg | Buy |
| 2024-11-19 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2024-11-08 | 업그레이드 | Goldman | Neutral → Buy |
| 2024-09-24 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2024-09-17 | 업그레이드 | Jefferies | Hold → Buy |
| 2024-09-16 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2024-08-07 | 업그레이드 | Deutsche Bank | Hold → Buy |
| 2024-08-02 | 업그레이드 | HSBC Securities | Hold → Buy |
| 2024-05-14 | 개시 | Evercore ISI | In-line |
| 2024-02-23 | 개시 | BMO Capital Markets | Outperform |
| 2024-01-05 | 개시 | Oppenheimer | Perform |
| 2023-12-01 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2023-10-16 | 다운그레이드 | HSBC Securities | Buy → Hold |
| 2023-07-14 | 개시 | HSBC Securities | Buy |
| 2023-05-17 | 업그레이드 | Redburn | Neutral → Buy |
| 2022-12-15 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2022-08-17 | 개시 | Cowen | Market Perform |
| 2022-07-13 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2022-07-06 | 재개 | Canaccord Genuity | Buy |
| 2022-02-01 | 업그레이드 | Redburn | Sell → Neutral |
| 2021-12-16 | 개시 | Morgan Stanley | Equal-Weight |
| 2021-11-10 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2021-10-22 | 개시 | Deutsche Bank | Hold |
| 2021-10-07 | 개시 | Jefferies | Hold |
| 2021-08-11 | 업그레이드 | Bryan Garnier | Neutral → Buy |
| 2021-07-19 | 재개 | Wolfe Research | Outperform |
| 2021-06-16 | 다운그레이드 | Redburn | Neutral → Sell |
| 2021-05-18 | 개시 | Goldman | Neutral |
| 2021-05-11 | 다운그레이드 | Bryan Garnier | Buy → Neutral |
| 2020-12-01 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2020-08-03 | 재개 | Berenberg | Buy |
| 2020-07-21 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2020-06-30 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2020-05-19 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2020-04-28 | 다운그레이드 | BofA/Merrill | Buy → Neutral |
| 2020-03-18 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2020-03-09 | 개시 | H.C. Wainwright | Neutral |
| 2020-01-24 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2020-01-22 | 다운그레이드 | UBS | Buy → Neutral |
| 2019-11-05 | 개시 | Wolfe Research | Outperform |
| 2019-11-04 | 개시 | Berenberg | Buy |
| 2019-11-04 | 개시 | BofA/Merrill | Buy |
| 2019-11-04 | 개시 | Canaccord Genuity | Buy |
| 2019-11-04 | 개시 | JP Morgan | Overweight |
| 2019-11-04 | 개시 | SVB Leerink | Outperform |
| 2019-11-04 | 개시 | UBS | Buy |
모두보기
바이오앤테크 주식(BNTX)의 최신 뉴스
BNTX Technical Analysis | Trend, Signals & Chart Patterns | BIONTECH SE-ADR (NASDAQ:BNTX) - ChartMill
BNTX Stock Quote Price and Forecast - CNN
Global Data for BioNTech and Bristol Myers Squibb’s PD-L1xVEGF-A Bispecific Pumitamig Shows Encouraging Efficacy in Patients with Non-Small Cell Lung Cancer in ROSETTA Lung-02 Trial - GlobeNewswire Inc.
BioNTech Juggles Vaccine Tweaks and Cancer Milestones as Investors Look Beyond COVID - aktiencheck.de
BioNTech Shows Its Hand at ASCO: A Pipeline in Full Bloom and a Radical Cost Overhaul () - aktiencheck.de
BioNTech upgraded to “buy” at UBS as next-gen cancer drugs de-risk - Investing.com
Caution with BioNTech! Novo Nordisk Accelerates! Buying Opportunity in Vidac Pharma Stock? - news.financial
BioNTech Faces Twin Test: Labor Strife Over 1,860 Jobs Meets ASCO’s Clinical Verdict () - aktiencheck.de
BioNTech Unveils $1B Buyback While Bernstein Flags Approval Risk Ahead of Oncology Data Dump - aktiencheck.de
BioNTech’s ctDNA Colorectal Cancer Study Signals Next Steps in Its Oncology Strategy - TipRanks
Bernstein initiates BioNTech stock coverage citing pipeline concerns - Investing.com
Bernstein initiates BioNTech stock coverage citing pipeline concerns By Investing.com - Investing.com South Africa
BNTX Stock Price, Quote & Chart | BIONTECH SE-ADR (NASDAQ:BNTX) - ChartMill
Nobel Laureate Karikó to Speak as BioNTech Cuts 1,860 Jobs in Oncology Pivot () - aktiencheck.de
BioNTech’s €500m Cost-Cutting Drive Fails to Lift Stock as Oncology Spending Soars () - aktiencheck.de
BioNTech Maps Oncology Push, $1B Buyback and Manufacturing Cuts at AGM - Yahoo Finance
Can Pfizer Achieve High Single-Digit Revenue CAGR From 2029? - TradingView
Analysts Offer Insights on Healthcare Companies: Argenx Se (ARGX), Siemens Healthineers AG (OtherSEMHF) and BioNTech SE (BNTX) - The Globe and Mail
BioNTech authorizes $1 billion share buyback program By Investing.com - Investing.com South Africa
BioNTech authorizes $1 billion share buyback program - Investing.com
BNTX Stock News: BioNTech Announces Layoffs as Covid-19 Revenue Slides - Barchart.com
BioNTech Earnings: Clinical Development on Track, Busy Schedule for the Remainder of the Year - Morningstar
Pfizer Beats on Q1 Earnings, New & Acquired Drugs Drive Sales Growth - sharewise.com
BioNTech Q1 Earnings Call Highlights - Yahoo Finance
BioNTech Q1 2026 Revenue Miss Overshadows Pipeline Progress as NASDAQ:BNTX Slides - ChartMill
BioNTech earnings ahead: Can oncology offset plunging vaccine sales? - Investing.com
Mitsubishi UFJ Trust & Banking Corp Sells 92,271 Shares of BioNTech SE Sponsored ADR $BNTX - MarketBeat
Pictet Asset Management Holding SA Buys 26,119 Shares of BioNTech SE Sponsored ADR $BNTX - MarketBeat
BioNTech’s Cancer Pivot Faces a Defining Week as Founders Head for the Door () - aktiencheck.de
SanDisk, Western Digital, Clorox And Other Big Stocks Moving Lower In Friday's Pre-Market Session - Sahm
BioNTech (NASDAQ:BNTX) Shares Gap DownWhat's Next? - MarketBeat
Pfizer, BioNTech Defeat Moderna COVID Jab Patent - Law360
BioNTech (BNTX) surges 6.1%: Is this an indication of further gains? - MSN
BioNTech SE Sponsored ADR $BNTX Shares Sold by Flossbach Von Storch SE - MarketBeat
Tangible book value per share of BioNTech SE Sponsored ADR – XETR:22UA - TradingView
BioNTech's $5.5 Million Insider Sale Precedes a Pivotal May for the Biotech () - aktiencheck.de
BioNTech SE (BNTX) Stock Price, Trades & News - GuruFocus
BioNTech SE (MEX:BNTXN) Stock Price, Trades & News - GuruFocus
Should You Buy, Hold, or Sell BMY Stock Ahead of Q1 Earnings? - TradingView
Sierk Poetting Sells 50,000 Shares of BioNTech (NASDAQ:BNTX) Stock - MarketBeat
BioNTech (BNTX) Surges 6.1%: Is This an Indication of Further Gains? - Yahoo Finance
BioNTech's Oncology Ambitions Hinge on Landmark Data and Shareholder Vote () - aktiencheck.de
Middle East Conflict Weighs on Markets: Food Supply Chains Become a Key Issue – MustGrow, K+S, Evotec, and BioNTech in the Spotlight - news.financial
BioNTech's Pancreatic Cancer Vaccine Shows Unprecedented Long-Term Survival () - aktiencheck.de
BioNTech's Oncology Pipeline Delivers Critical Data as Strategic Pivot Accelerates () - aktiencheck.de
BNTX Earnings History & Surprises | EPS & Revenue Results | BIONTECH SE-ADR (NASDAQ:BNTX) - ChartMill
BioNTech’s Malaria mRNA Vaccine Trial Reaches Completion: What Investors Should Watch - TipRanks
Lbp Am Sa Acquires 15,255 Shares of BioNTech SE Sponsored ADR $BNTX - MarketBeat
바이오앤테크 (BNTX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.02%
0.19%
자본화:
|
볼륨(24시간):